通用型CAR-T在实现技术突破后,又迎来投融资、支付环境的转暖。 在细胞治疗领域,一场类似DeepSeek的变革正在发生,科济药业以连续节点性进展推动CAR-T转向高效率低成本模式。 2月25日,科济药业宣布与珠海软银合作,共同投资通用型CAR-T Biotech优恺泽,投资后科济药业仍拥有92%的股权,对优恺泽具有控制权。 根据协议条款计算,优恺泽估值10亿元,其管线资产为通用型BCMA CAR...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.